Generation of a multipathogen-specific T-cell product for adoptive immunotherapy based on activation-dependent expression of CD154.
about
Adoptive T-cell therapy for fungal infections in haematology patientsMonitoring of pathogen-specific T-cell immune reconstitution after allogeneic hematopoietic stem cell transplantationRecent Developments in Cellular Immunotherapy for HSCT-Associated ComplicationsInduction of A. fumigatus-specific CD4-positive T cells in patients recovering from invasive aspergillosis.Adenovirus infections in immunocompetent and immunocompromised patients.Distinct and complementary roles for Aspergillus fumigatus-specific Tr1 and Foxp3+ regulatory T cells in humans and mice.Strategies to harness immunity against infectious pathogens after haploidentical stem cell transplantationRapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infectionsImmunologic special forces: anti-pathogen cytotoxic T-lymphocyte immunotherapy following hematopoietic stem cell transplantation.T cells for viral infections after allogeneic hematopoietic stem cell transplantImmune recovery in HIV-infected patients after Candida esophagitis is impaired despite long-term antiretroviral therapyManagement of adenovirus in children after allogeneic hematopoietic stem cell transplantation.Immunotherapy for opportunistic infections: Current status and future perspectives.Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma.Immunotherapy against invasive mold infections.Emerging concepts in haematopoietic cell transplantation.Therapeutic strategies for the prevention and treatment of cytomegalovirus infection.Universal fungal vaccines: could there be light at the end of the tunnel?Recent progress in managing graft-versus-host disease and viral infections following allogeneic stem cell transplantation.Immunotherapy of invasive fungal infection in hematopoietic stem cell transplant recipients.Diagnosis and treatment of adenovirus infection in immunocompromised patients.Protective immune responses to fungal infections.Immunotherapy for viral and fungal infections.Immunotherapy of Fungal Infections.Immunotherapy for infectious diseases in haematological immunocompromise.Natural killer cell-mediated damage of clinical isolates of mucormycetes.Comparative Analysis of Clinical-Scale IFN-γ-Positive T-Cell Enrichment Using Partially and Fully Integrated Platforms.Artificial antigen-presenting cells expressing HLA class II molecules as an effective tool for amplifying human specific memory CD4(+) T cells.Multispecific Aspergillus T cells selected by CD137 or CD154 induce protective immune responses against the most relevant mold infections.Differential expression of THELPER 1 cytokines upon antigen stimulation predicts ex vivo proliferative potential and cytokine production of virus-specific T cells following re-stimulation.Targeting EBV's Achilles' heel with antigen-specific T cells.Characterization of the T-cell-mediated immune response against the Aspergillus fumigatus proteins Crf1 and catalase 1 in healthy individuals.Adoptive T-cell immunotherapy from third-party donors: characterization of donors and set up of a T-cell donor registry.Successful isolation and expansion of CMV-reactive T cells from G-CSF mobilized donors that retain a strong cytotoxic effector function.
P2860
Q26781064-FD0784E5-774A-4F07-818A-29930D0B8070Q26861648-7BCB9F63-9E3B-484F-AEFA-9B2505D6E7D3Q28079823-EA68D602-6BEB-4E4F-B028-33B1F8A9844FQ33828598-FFB22D98-8DEF-44F3-AB8D-4AC8585B2437Q34057627-D232926B-B4D8-4BF3-8265-CB6EF52DE2E4Q34207966-36B32FA8-5AD5-4673-A167-BC5B01EC0FA3Q35485612-EB8F6A5D-BE3A-481E-A489-5DA43DD05871Q36142490-07F0AC10-A657-4CF5-A7D7-9B7F1FA9B496Q36956443-EE8FD51D-4578-4606-9FA3-EA093ACA9B66Q37058107-B2D9566E-2EEA-478A-91DA-A931AACEB183Q37104112-7A2FF4B2-845C-4CF0-A428-D2ECB507F5CBQ37316282-6095A5DB-616C-47CA-B10A-BBEA78E61C0BQ37509216-6D28AF2D-A651-4A48-A944-75A58D7FE684Q37690437-3DAE2DFA-306B-40B0-8F12-30BC854AF8BEQ37965757-4CFFB55B-2354-4ED4-8537-16E577820DA5Q38013047-286583D2-9394-4B51-95E6-E7F9952DCE60Q38014916-0E4DE927-B860-4E7B-A05C-7CEF1B48C723Q38038044-9CF7A2FA-BB79-4FD7-8078-34A60DF87C7FQ38066586-D0CF9F44-0988-498F-BF00-A0A2693EE6B9Q38081105-EF64E753-462B-4544-8D0E-6FA5BD139CB6Q38145327-04928513-5F2B-4B69-A279-5F67F2960D6AQ38247209-4EAEE443-AB5A-427C-86A9-AACCC56A0C33Q38514499-F8E24673-345C-417C-9845-BCF6F1CA7756Q38635409-98172E96-347D-488F-8C7A-21CD631C1A17Q39215653-536907C9-CD71-499D-80C7-74B36AD6AD3BQ40310934-F0E085B1-2794-4B9B-B4EA-EEFFCF12B0B5Q40504861-234831F2-3444-4641-BCE8-4E38FB638623Q40774020-AFE99715-2371-4CA4-90CC-47867C92845FQ41678768-84AC5325-5C5C-4D64-B50D-6FF70C5820F1Q41748023-B01D084F-F176-4300-AB84-983B4CD80358Q42034589-4813BDE1-5328-4367-BE49-4B503010CC3EQ42261981-B1CD28CF-524D-4237-A3A5-16BAD5152344Q42271011-300FFBE3-8407-4E05-A7C3-3CE035EA9B37Q44993238-63E60B54-D410-4B28-BA36-66D3AE6BF639
P2860
Generation of a multipathogen-specific T-cell product for adoptive immunotherapy based on activation-dependent expression of CD154.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Generation of a multipathogen- ...... dependent expression of CD154.
@en
Generation of a multipathogen- ...... dependent expression of CD154.
@nl
type
label
Generation of a multipathogen- ...... dependent expression of CD154.
@en
Generation of a multipathogen- ...... dependent expression of CD154.
@nl
prefLabel
Generation of a multipathogen- ...... dependent expression of CD154.
@en
Generation of a multipathogen- ...... dependent expression of CD154.
@nl
P2093
P1433
P1476
Generation of a multipathogen- ...... -dependent expression of CD154
@en
P2093
Barbara Conrad
Carsten Berges
Claudia Stuehler
Max S Topp
Nina Khanna
Sarah Lurati
P304
P356
10.1182/BLOOD-2010-12-322610
P407
P577
2011-06-03T00:00:00Z